玻璃体内注射贝伐单抗后的边缘角膜炎

IF 2.8 3区医学 Q1 OPHTHALMOLOGY Acta Ophthalmologica Pub Date : 2025-01-19 DOI:10.1111/aos.17201

Clara Lara Aroco, María de los Ángeles Ibáñez Ruiz, Silvia Beatriz De Miguel Martín, Rosa María Jiménez Escribano

{"title":"玻璃体内注射贝伐单抗后的边缘角膜炎","authors":"Clara Lara Aroco, María de los Ángeles Ibáñez Ruiz, Silvia Beatriz De Miguel Martín, Rosa María Jiménez Escribano","doi":"10.1111/aos.17201","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <p><b>Aims/Purpose:</b> To report a case of marginal keratitis that developed after intravitreal bevacizumab (Avastin) injection.</p>\n \n <p><b>Methods:</b> A 88-year-old woman with Age-related macular degeneration (AMD) and macular edema in both eyes received four intravitreal injection of bevacizumab (Avastin) in left eye and five in right eye. No previous history of herpes.</p>\n \n <p><b>Results:</b> Two days following the fifth injection of Avastin in the patient's right eye, she experienced sensations akin to having a foreign body, accompanied by redness and a decrease in visual acuity in that eye. Examination with a slit lamp revealed peripheral infiltrates beneath the corneal epithelium, delineated from the limbus by a clear zone. Additionally, there was corneal edema with folds in the endothelium and a mild anterior chamber reaction. No presence of hypopyon was noted. The patient's symptoms showed favorable response to topical steroid and topic and oral antibiotic medications</p>\n \n <p><b>Conclusions:</b> The intravitreal administration of bevacizumab carries a risk of inducing hypersensitivity reactions like marginal keratitis. To our knowledge, this is the first documented account of marginal keratitis after intravitreal bevacizumab injection.</p>\n \n <div><b>References</b><ol>\n \n <li>Farrell DA, Deacon S, Mauger T. \"Marginal keratitis following COVID 19 vaccination\". IDCases. 2022 Jun 15; 29: e01536. doi: 10.1016/j.idcr.2022.e01536. PMID: 35756698; PMCID: PMC9212909</li>\n \n <li>Aslan Bayhan S, Bayhan HA, Adam M, Gürdal C. Marginal keratitis after intravitreal injection of ranibizumab. Cornea. 2014 Nov; 33(11): 1238-9. doi: 10.1097/ICO.0000000000000255. PMID: 25222003</li>\n </ol>\n </div>\n </section>\n </div>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":"103 S284","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/10.1111/aos.17201","citationCount":"0","resultStr":"{\"title\":\"Marginal keratitis after intravitreal injection of bevacizumab\",\"authors\":\"Clara Lara Aroco, María de los Ángeles Ibáñez Ruiz, Silvia Beatriz De Miguel Martín, Rosa María Jiménez Escribano\",\"doi\":\"10.1111/aos.17201\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <p><b>Aims/Purpose:</b> To report a case of marginal keratitis that developed after intravitreal bevacizumab (Avastin) injection.</p>\\n \\n <p><b>Methods:</b> A 88-year-old woman with Age-related macular degeneration (AMD) and macular edema in both eyes received four intravitreal injection of bevacizumab (Avastin) in left eye and five in right eye. No previous history of herpes.</p>\\n \\n <p><b>Results:</b> Two days following the fifth injection of Avastin in the patient's right eye, she experienced sensations akin to having a foreign body, accompanied by redness and a decrease in visual acuity in that eye. Examination with a slit lamp revealed peripheral infiltrates beneath the corneal epithelium, delineated from the limbus by a clear zone. Additionally, there was corneal edema with folds in the endothelium and a mild anterior chamber reaction. No presence of hypopyon was noted. The patient's symptoms showed favorable response to topical steroid and topic and oral antibiotic medications</p>\\n \\n <p><b>Conclusions:</b> The intravitreal administration of bevacizumab carries a risk of inducing hypersensitivity reactions like marginal keratitis. To our knowledge, this is the first documented account of marginal keratitis after intravitreal bevacizumab injection.</p>\\n \\n <div><b>References</b><ol>\\n \\n <li>Farrell DA, Deacon S, Mauger T. \\\"Marginal keratitis following COVID 19 vaccination\\\". IDCases. 2022 Jun 15; 29: e01536. doi: 10.1016/j.idcr.2022.e01536. PMID: 35756698; PMCID: PMC9212909</li>\\n \\n <li>Aslan Bayhan S, Bayhan HA, Adam M, Gürdal C. Marginal keratitis after intravitreal injection of ranibizumab. Cornea. 2014 Nov; 33(11): 1238-9. doi: 10.1097/ICO.0000000000000255. PMID: 25222003</li>\\n </ol>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":6915,\"journal\":{\"name\":\"Acta Ophthalmologica\",\"volume\":\"103 S284\",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-01-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/10.1111/aos.17201\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Ophthalmologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/aos.17201\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Ophthalmologica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aos.17201","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的/目的：报告一例玻璃体内注射贝伐单抗（阿瓦斯汀）后发生的边缘角膜炎。方法：一名88岁的老年性黄斑变性（AMD）伴双眼黄斑水肿的女性患者，在左眼和右眼分别接受4次贝伐单抗（阿瓦斯汀）玻璃体内注射。既往无疱疹病史。结果：在患者右眼注射第五次阿瓦斯汀两天后，她经历了类似异物的感觉，并伴有眼睛发红和视力下降。裂隙灯检查显示角膜上皮下有外周浸润，从角膜边缘处可见清晰区。此外，角膜水肿，内皮皱褶和轻度前房反应。未发现假说的存在。结论：玻璃体腔内给药贝伐单抗存在诱发边缘角膜炎等超敏反应的风险。据我们所知，这是玻璃体内注射贝伐单抗后边缘性角膜炎的第一个记录。参考文献Farrell DA， Deacon S, Mauger T。“COVID - 19疫苗接种后的边缘角膜炎”。IDCases。2022年6月15日；29: e01536。doi: 10.1016 / j.idcr.2022.e01536。PMID: 35756698;Aslan Bayhan S, Bayhan HA, Adam M, g rdal C.玻璃体内注射雷尼单抗后的边缘角膜炎。2014年11月；33(11): 1238 - 9。doi: 10.1097 / ICO.0000000000000255。PMID: 25222003

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Marginal keratitis after intravitreal injection of bevacizumab

Aims/Purpose: To report a case of marginal keratitis that developed after intravitreal bevacizumab (Avastin) injection.

Methods: A 88-year-old woman with Age-related macular degeneration (AMD) and macular edema in both eyes received four intravitreal injection of bevacizumab (Avastin) in left eye and five in right eye. No previous history of herpes.

Results: Two days following the fifth injection of Avastin in the patient's right eye, she experienced sensations akin to having a foreign body, accompanied by redness and a decrease in visual acuity in that eye. Examination with a slit lamp revealed peripheral infiltrates beneath the corneal epithelium, delineated from the limbus by a clear zone. Additionally, there was corneal edema with folds in the endothelium and a mild anterior chamber reaction. No presence of hypopyon was noted. The patient's symptoms showed favorable response to topical steroid and topic and oral antibiotic medications

Conclusions: The intravitreal administration of bevacizumab carries a risk of inducing hypersensitivity reactions like marginal keratitis. To our knowledge, this is the first documented account of marginal keratitis after intravitreal bevacizumab injection.

References

Farrell DA, Deacon S, Mauger T. "Marginal keratitis following COVID 19 vaccination". IDCases. 2022 Jun 15; 29: e01536. doi: 10.1016/j.idcr.2022.e01536. PMID: 35756698; PMCID: PMC9212909
Aslan Bayhan S, Bayhan HA, Adam M, Gürdal C. Marginal keratitis after intravitreal injection of ranibizumab. Cornea. 2014 Nov; 33(11): 1238-9. doi: 10.1097/ICO.0000000000000255. PMID: 25222003

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Acta Ophthalmologica 医学-眼科学

CiteScore

7.60

自引率

5.90%

发文量

433

审稿时长

6 months

期刊介绍： Acta Ophthalmologica is published on behalf of the Acta Ophthalmologica Scandinavica Foundation and is the official scientific publication of the following societies: The Danish Ophthalmological Society, The Finnish Ophthalmological Society, The Icelandic Ophthalmological Society, The Norwegian Ophthalmological Society and The Swedish Ophthalmological Society, and also the European Association for Vision and Eye Research (EVER). Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses.